Anti-MAG Neuropathy Serum

Human Anti-MAG Neuropathy Serum for Research

Our Anti-Myelin-Associated Glycoprotein (MAG) Autoimmune Neuropathy Serum is sourced from IRB-consented donors clinically diagnosed with anti-MAG neuropathy. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for autoantibody, biomarker, and demyelination research.

About Anti-MAG Neuropathy

Anti-MAG neuropathy is an autoimmune demyelinating peripheral neuropathy driven by IgM autoantibodies against myelin-associated glycoprotein, a component of the periaxonal Schwann cell membrane. In most cases the IgM is monoclonal and arises from an underlying IgM monoclonal gammopathy of undetermined significance (MGUS) or, less often, Waldenström macroglobulinaemia — so the condition sits at the intersection of neurology and clonal B-cell disease.

Clinically it presents as a slowly progressive, distal, predominantly sensory neuropathy with prominent sensory ataxia and tremor — the phenotype often described as DADS (distal acquired demyelinating symmetric neuropathy). Because pathogenicity correlates with anti-MAG antibody titre, and because the antibodies are the direct effector, donor serum is the primary research material rather than a surrogate: it contains the pathogenic species itself.

Donor Stratification Available

• Anti-MAG antibody titre where tested (Bühlmann titre units)
• IgM paraprotein status — presence and quantification of monoclonal IgM
• Underlying haematological diagnosis — IgM MGUS or Waldenström macroglobulinaemia
• Disease severity and duration, including ataxia and tremor involvement
• Treatment status — treatment-naive and rituximab- or immunotherapy-treated donors
• Matched healthy controls available

Product Features

• Collected from clinically confirmed Anti-MAG Neuropathy donors
• Research Use Only (RUO)
• IRB-approved protocols with documented consent
• Custom aliquot volumes available upon request
• High-titre donors prioritised where required for assay work

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and ethnicity
• Donor-reported medical history and comorbidities
• Electrophysiology findings where available

Applications

• Anti-MAG antibody detection, titration, and assay development
• Epitope mapping against MAG and related HNK-1 glycoepitopes
• Complement activation and demyelination mechanism studies
• Biomarker discovery for anti-MAG neuropathy
• Serum cytokine and protein profiling
• Therapeutic candidate screening and validation, including B-cell-directed approaches

Other Anti-MAG Neuropathy Specimen Types

Matched material from the same donor cohort is available as anti-MAG neuropathy plasma, whole blood, and PBMC. For related demyelinating cohorts see CIDP serum.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering and Customization

Anti-MAG neuropathy serum is available in standard and custom volumes. For international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For the full specimen range, see our human serum collection.